UOC
CELU icon

UBS O'Connor’s Celularity CELU Stock Holding History

UBS O'Connor’s Portfolio CELU Stock Details CELU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-57,031
Closed -$6.27M – 826
2020
Q4 		$6.27M Sell
57,031
-6,844
-11% -$727K 0.13% 168
2020
Q3 		$6.71M Sell
63,875
-25,900
-29% -$2.68M 0.17% 91
2020
Q2 		$9.16M Sell
89,775
-4,725
-5% -$469K 0.2% 122
2020
Q1 		$9.26M Buy
+94,500
New +$9.35M 0.19% 101

Other funds holding CELU

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

UBS O'Connor's CELU Position: Q1 2021 in Review

UBS O'Connor sold out of Celularity (CELU) in Q1 2021, closing a stake of 57,031 shares — an estimated $6.27M sold.

UBS O'Connor first reported a position in CELU in Q1 2020 and held it in 4 quarters. The position peaked at $9.26M in Q1 2020. 63 funds tracked by Wall St. Rank hold CELU as of Q1 2021.

  • UBS O'Connor reported no remaining Celularity position as of Q1 2021 after selling out during the quarter.
  • UBS O'Connor sold 57,031 Celularity shares in Q1 2021, an estimated $6.27M.
  • UBS O'Connor first reported a position in Celularity in Q1 2020 and held it in 4 quarters.
  • UBS O'Connor's Celularity position peaked at $9.26M in Q1 2020.
  • 63 funds tracked by Wall St. Rank held Celularity as of Q1 2021.

Based on UBS O'Connor's 13F filing for Q1 2021, filed 14 May 2021.